Study: Semaglutide May Repair Kidney Vessels and Reduce Inflammation
Drugs like Ozempic may help treat chronic kidney disease by repairing and restoring the blood vessels that power the body’s waste disposal systems, according to a study published October 1 in Nature Medicine.
-
Key Clinical Takeaways:
- Semaglutide increased blood flow and reduced inflammation in patients with chronic kidney disease, improving the health of tiny blood vessels called glomeruli.
- Participants taking the drug showed reduced scarring, lower blood vessel stiffness, and decreased levels of urinary albumin compared to those on a placebo.
- Genetic analysis revealed that semaglutide turned off metabolic stress and inflammatory genes while switching on repair genes.
Chronic kidney disease affects an estimated 674 million people worldwide, with diabetes and high blood pressure among its most common causes. Over time, as the disorder advances, organs gradually lose their capability to extract metabolic waste from the bloodstream and pass it out through urine.
This loss of function causes other health complications and sharply increases the risk of dying from a heart attack or stroke. Research published in 2024 within the New England Journal of Medicine indicated that individuals suffering from diabetic chronic kidney disease who received semaglutide experienced lower rates of renal failure, fatal heart attacks, and fatal strokes relative to a control group receiving a dummy pill.
Investigators halted that clinical trial prematurely because the medication demonstrated such a high degree of efficacy in preventing mortality that researchers deemed it unethical to continue administering the placebo.
For the new study, some of the same researchers looked at a subset of 106 participants to find out how the drug worked. The team collected kidney tissue samples before and after participants took semaglutide and compared them with samples from participants given the placebo.
Administration of semaglutide produced striking macroscopic alterations in the tissue samples, featuring enhanced circulation, lessened fibrosis, and diminished arterial rigidity. Increased blood flow matters because it increases filtration, which is the main job of the kidneys, according to Peter Nguyen, a nephrologist at Houston Methodist Hospital who was not involved in the study.
Researchers also measured albumin levels in patients' urine; high levels indicate kidney filter failure. While those levels did not change much in patients on the placebo, they dropped in patients taking semaglutide.
The research team looked under the hood for genetic clues to how semaglutide healed the kidneys. Katherine Tuttle—a nephrologist at the University of Washington’s Providence Medical Research Center in Spokane—and her collaborators discovered that inside the tiny filtering units known as glomeruli, genes associated with metabolic distress were deactivated.
Within these same cells, inflammatory genes were also turned off while repair genes were switched on. Before semaglutide treatment, blood vessels and immune cells sent lots of inflammatory signals to each other, Tuttle reported.
After semaglutide treatment, the immune cells went quiet and silenced messages that ramp up harmful inflammation. Susan Quaggin, a specialist in renal medicine at Northwestern University Feinberg School of Medicine located in Chicago—who did not participate in the research—observed that the findings corroborate the established anti-inflammatory properties of GLP-1 receptor agonists while also pointing toward a direct mechanism for safeguarding renal vasculature.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.